NCT07295704 Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
| NCT ID | NCT07295704 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The General Authority for Teaching Hospitals and Institutes |
| Condition | Micropulse Laser |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-10-15 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Both sexes. * Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20/400 or better, and center-involved DME \[defined as a central macular thickness (CMT) of \>250 but \<700µm measured by spectral-domain optical coherence tomography\]. * Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA). Exclusion Criteria: * Monocular eyes. * Chronic renal failure or renal transplant because of diabetic nephropathy. * Glycated hemoglobin (HbA1c) of more than 10%. * Vitreomacular traction syndrome. * Epiretinal membrane. * PRP within 4months before the treatment. * Intraocular surgery within 6months, including cataract or vitreoretinal operation. * Rubeosis iridis. * Severe glaucoma. * High-risk proliferative diabetic retinopathy. * Poor dilation. * Increased foveal avascular zone. * Any condition that could interfere with optical coherence tomography (OCT) measurement or visual acuity.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07295704 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Micropulse Laser. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07295704 currently recruiting?
Yes, NCT07295704 is actively recruiting participants. Contact the research team at Dr.hossameabdalfataah@gothi.gov.eg for enrollment information.
Where is the NCT07295704 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07295704 clinical trial?
NCT07295704 is sponsored by The General Authority for Teaching Hospitals and Institutes. The trial plans to enroll 50 participants.